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The renal bumetanide-sensitive Na-K-2Cl cotransporter
(NKCC2) is themajor salt transport pathway in the apical mem-
brane of themammalian thick ascending limb. It is differentially
spliced and the three major variants (A, B, and F) differ in their
localization and transport characteristics. Most knowledge
about its regulation comes from experiments in Xenopus
oocytes as NKCC2 proved difficult to functionally express in a
mammalian system. Here we report the cloning and functional
expression of untagged and unmodified versions of the major
splice variants from ferret kidney (fNKCC2A, -B, and -F) in
human embryonic kidney (HEK) 293 cells. Many NKCC2 anti-
bodies used in this study detected high molecular weight forms
of the transfectedproteins, probablyNKCC2dimers, but not the
monomers. Interestingly, monomers were strongly detected by
phosphospecific antibodies directed against phosphopeptides
in the regulatoryN terminus. Bumetanide-sensitive 86Rbuptake
was significantly higher in transfected HEK-293 cells and could
be stimulated by incubating cells in a medium containing a
low chloride concentration prior the uptake measurements.
fNKCC2 was less sensitive to the reduction in chloride concen-
tration than NKCC1. Using HEK-293 cells stably expressing
fNKCC2Awealso show that co-expressionof variantNKCC2AF
does not have the dominant-negative effect onNKCC2Aactivity
that was seen in Xenopus oocytes, nor is it trafficked to the cell
surface. In addition, fNKCC2AF is neither complex glycosylated
nor phosphorylated in its N terminus regulatory region like
other variants.
TheNa-K-2Cl cotransporter, isoform2 (SLC12A1; NKCC2)2
plays key roles in regulating body salt levels and blood pressure
(1–3). Located in the apicalmembrane and subapical vesicles in
the thick ascending limb of the Henle loop in the mammalian
kidney it is responsible for reabsorbing about 20% of filtered
NaCl. In the macula densa it is also essential in tubuloglomeru-
lar feedback, themechanism thatmatches glomerular filtration
to tubular reabsorption. NKCC2 is the clinical target for loop
diuretics, defects in its operation cause Bartter disease and
its dysregulation may contribute to essential hypertension.
Despite its importance relatively little work has been carried
out directly on NKCC2 mainly due to difficulties in expressing
mammalianNKCC2 in a functionally competent form inmam-
malian cells (4, 5). Chimeric (6) or tagged (7) versions have been
functionally expressed in mammalian cells, as have the native
proteins in Xenopus oocytes (8, 9), but it is unclear to what
extent these reflect the behavior of the native transporter in
vivo. In addition, although these studies provide important
information on transport kinetics and ion affinities (10, 11) they
reveal little about transport regulation. Current opinion is
based largely through homology on the behavior of closely
related NKCC1, which has been successfully expressed and
extensively studied (1).
NKCC1 activity is strongly dependent on the phosphoryla-
tion of a group of threonine residues in a regulatory domain in
its N terminus (Fig. 1A) (12, 13). At rest these residues are pre-
dominantly unphosphorylated and transport rate is very low.
On stimulation, these residues, and in particular that equiv-
alent to Thr217 in the human protein, become phosphoryla-
ted and the transport rate increases manyfold. One potent
stimulus is a fall in cell chloride concentration that causes
phosphorylation and activation of SPAK and OSR1, kinases
that phosphorylate threonine residues in this regulatory
domain (13–16). A very similar motif exists in the N termi-
nus of NKCC2. Recent work shows that ion transport by
NKCC2 is affected by phosphorylation or mutation of thre-
onine residues in this motif, and by reduction of cell chloride
concentration (17–19). Thus these initial studies suggest
aspects of the regulation of NKCC2 are similar to those
found with NKCC1, however, essential features remain to be
discovered.
Understanding the regulation of NKCC2 is further compli-
cated as the transporter exists in at least 4 splice variants: A, B,
and F, which are identical to one another except for a 96-bp
exon that encodes for the second transmembrane domain (TM)
and part of the first intracellular loop, and AF, which possesses
both the A and F exons in tandem (2, 4, 20–23). These differ in
their location within the thick ascending limb of theHenle loop
and, as the variable region is involved in ion binding, have dif-
ferent affinities for sodium, potassium, and chloride that are
appropriate for the composition of urine in part of the thick
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ascending limb of the Henle loop where they are expressed.
ThusNKCC2F,which has the lowest affinity for all three ions, is
found exclusively in the medulla, NKCC2A is in both medulla
and cortex, and NKCC2B, which has the highest chloride affin-
ity, is exclusively in the macula densa. Both NKCC2A and
NKCC2B are involved in tubuloglomerular feedback (24). It is
likely that regulation of these variants differs to reflect function,
NKCC2F being more involved in mass transport and NKCC2B
in signaling. The role of other splice variants, predominant
amongwhich is NKCC2AF, is not clear. A role in regulation has
been suggested. For instance, although NKCC2AF does not
transport ions it has a dominant-negative effect on other
NKCC2 variants when co-expressed in oocytes (22).
Here we report the cloning and expression of 4 variants of
NKCC2 from ferret (Mustela putorius furo) kidney samples
(fNKCC2A, -B, -F, and -AF). The material became available
during studies on related NKCC1, where the ferret red blood
cells was shown to be a powerful functional model (25). Ferrets,
like dogs, are members of the order Carnivora and are used to
model human physiology in studies of cardiovascular function.
We find significantly higher bumetanide-sensitive fluxes in
HEK-293 cells transfected with fNKCC2A, -B and -F but not
with -AF. UsingHEK-293 cells stably expressing fNKCC2A, we
demonstrate that the behavior of fNKCC2AF differs signifi-
cantly from that reported following expression in Xenopus
oocytes. We also show that many antipeptide antibodies fail to
detect expressed fNKCC2 at the expected monomeric molecu-
lar weight.
EXPERIMENTAL PROCEDURES
Solutions and Chemicals—All solutions were prepared in
Milli-Q water (Millipore, Billerica, MA) using analytical grade
chemicals where possible. Unless otherwise stated, the pH was
adjusted with NaOH at the appropriate temperature. Lysis
buffer comprised (in mM): 50 sodium fluoride, 5 Na4P2O7, 5
EDTA, 1 sodium orthovanadate, 1% Triton X-100, 1% protease
inhibitor cocktail (PIC, Calbiochem), and 20 HEPES, pH 7.4.
Two-dimensional gel electrophoresis lysis buffer (inmM)was: 2
sodium fluoride, 2 Na4P2O7, 2 EDTA, 1 sodium orthovanadate,
1% Triton X-100, 1% PIC, 10 Tris-HCl, pH 7.5. PBS was com-
prised (inmM) of: 137NaCl, 10Na2HPO4, 1.7 KH2PO4, 2.8 KCl.
RNA Isolation and Cloning of Ferret NKCC2—Total RNA
was prepared from ferret kidneys stored in RNALater (Qiagen)
using the PureLinkMicro-to-Midi Total RNAPurification Sys-
tem according to the manufacturer’s instructions (Invitrogen).
5- and 3-regions of the slc12a1 gene sequences were obtained
using the GeneRacer protocol (Invitrogen). Ferret kidney
mRNA was ligated to a GeneRacer RNA-oligo containing
known priming sites for subsequent PCRs and reverse tran-
scribed using GeneRacer oligo(dT) primer or random hexam-
ers as primers and SuperScript III reverse transcriptase. 5- and
3-RACE (rapid amplification of cDNA ends)-PCR and nested
PCR were performed according to the manufacturer’s instruc-
tions, using GeneRacer primers and gene-specific primers
based on conserved regions of known vertebrate slc12a1 gene
sequences (5 RACE-PCR, 5-CAGGCATCCCATCACCGT
TAG CAA CC-3; 3 RACE-PCR, 5-GAG CTA CCG CCA
AGT TCG ACT GAA TGA-3; 3 nested RACE-PCR, 5-GGA
AAT CCT CAC AAA GAA CCT CCC TCC T-3). PCR prod-
ucts were purified, cloned into the pCR4Blunt-TOPO vector,
and sequenced (CoGenics, Essex, UK).
The complete open reading frame of the slc12a1 gene was
amplified from the oligo(dT)-transcribed ferret kidney cDNA
pool using primers based on our sequence data (sense primer,
5-GGAAGATGT TCT CTGAACAACACT T-3; antisense
primer, 5-CAT GGA TTA AGA GTA AAA TGT CAG TAC-
3). Purified PCR products were cloned into pCR4Blunt-TOPO
vector and sequenced. This revealed the presence of four dif-
ferent splice variants, fNKCC2A, -B, -F, and –AF, all of which
were subcloned by excision from their respective pCR4Blunt-
TOPO construct at the EcoRI sites flanking the polylinker,
and ligation into the EcoRI site of mammalian expression
vectors pcDNA3.1 (Invitrogen) or pCI-neo (Promega, Mad-
ison, WI). Clones were selected for correct orientation of the
open reading frame within the construct by colony PCR and
subsequently sequenced in both directions. Sequence data
have been deposited at GenBankTM under accession num-
bers GQ338079, GQ338080, and GQ338081 (fNKCC2A, -B,
and –F, respectively).
Cell Culture, Transfection, and Stable Cell Lines—HEK-293
cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% heat-inactivated fetal bovine serum,
100 units/ml of penicillin, 100g/ml of streptomycin, and 4mM
L-glutamine. All cells were maintained at 37 °C in a water-sat-
urated atmosphere containing 95% air and 5% CO2. Cells were
split into 6- or 24-well plates the day before transfection. At
60–70% confluence, HEK-293 cells were transfected with the
appropriate expression vectors using ExGen 500 (Fermentas,
Ontario, Canada) according to themanufacturer’s instructions.
Stable transfectants were selected by growth in the presence of
0.3 mg/ml of Geneticin (Invitrogen).
86Rb Uptake Studies—24 h after transfection in 6-well plates,
HEK-293 cells were subcultured onto poly-D-lysine-coated
96-well plates and grown to confluence for 2 days before the
86Rb uptake assay was carried out. For measurement of 86Rb
uptake in stable transfectedHEK-293 cells, the cells were plated
directly onto poly-D-lysine-coated 96-well plates and grown to
confluence for 2–3 days.
Fluxes were measured at room temperature using a modifi-
cation of a well established method (26). Before each flux assay
cells were washed and briefly incubated in basic medium (in
mM: 135 NaCl, 2.5 KCl, 1 CaCl2, 1MgCl2, 5 glucose, 15 HEPES,
pH 7.4). Basal fluxes were then measured following further
incubation (up to 60min) in basic medium, whereas stimulated
cotransporter fluxes were measured following 2 washes and 60
min of incubation in a hypotonic/low-chloridemedium (inmM:
67.5 sodium gluconate, 2.5 potassium gluconate, 0.5 CaCl2, 0.5
MgCl2, 5 glucose, 15 HEPES, pH 7.4). Following these incuba-
tions cells were briefly washed in the same incubation medium
but with the addition of 0.1 mM ouabain and, where indicated,
10Mbumetanide. 86Rb uptakewas thenmeasured for 3min (7
min when bumetanide present) in flux medium (in mM: 135
NaCl, 1 RbCl, 1 CaCl2, 1 MgCl2, 5 glucose, 0.1 ouabain, 15
HEPES, pH 7.4). 86Rb uptake was terminated by removing the
flux medium and washing cells three times in cold 110 mM
MgCl2 using an automatic plate washer (Multiwash III; Tri-
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Continent, Grass Valley, CA). Cell 86Rb was determined with a
Typhoon PhosphorImager (GE Healthcare). At least 3 wells
were used for each experimental point. Cell protein content for
each construct was determined from wells that had not
received 86Rb. Cells were lysed in lysis buffer and protein con-
centration was determined using the BCA protein assay
(Pierce).
Primary Antibodies—NKCC1-specific antibody (N1) was
raised in rabbits to two peptides (71PLGPTPSQSRFQVD84 and
240RPSLAELHDELEKEPF255) in the N terminus of human
NKCC1 and was affinity purified before use (CovalAb, Villeur-
banne, France). The NKCC2-specific antibody (N2-Ct) was
generated similarly using a peptide located in the C terminus
(1005CKDLTTAEKLKRES1018) of fNKCC2. Other primary
antibodies used in this study where either gifts (anti-NKCC2
and anti-pNKCC, D. Alessi (Dundee, UK); R5, B. Forbush
(Yale); L224, M. Knepper (National Institutes of Health)) or
commercial (T4, Developmental Studies Hybridoma Bank,
Iowa City, IA; NKCC2, Alpha Diagnostics, San Antonio, TX).
Sample Preparation—Protein was isolated from HEK-293
cells 48 h after transfection using either standard or two-
dimensional gel electrophoresis lysis buffer. Crude membrane
extracts from ferret and rat kidneys were prepared by homog-
enization in 250 mM sucrose, 10 mM triethanolamine, 2% PIC
followed by sequential centrifugations at 1,000 (10 min) and
17,000  g (20 min). The resulting crude membrane fraction
was stored in liquid nitrogen until use. The protein content of
all lysates was determined using a BCA protein assay.
Western Blots—Proteins were separated on NuPAGE 3–8%
Tris acetate gels (Invitrogen), transferred to polyvinylidene
difluoride membranes, and blocked. Blots were incubated with
primary antibody in blocking buffer overnight at 4 °C (seeTable
1), washed, and incubated with the appropriate horseradish
peroxidase-conjugated secondary antibody for 1 h at room
temperature. Antibody binding was quantified using Immo-
bilon ECL reagents (Millipore) and Hyperfilm (GE Healthcare)
and scanned blots were analyzed with TotalLab (Non Linear
Dynamics, Newcastle, UK). Membranes were stripped (62.5
mM Tris-HCl, pH 6.8, 2% SDS) for 60 min at 70 °C, blocked,
and all subsequent steps carried out as described above to rep-
robe blots with a different antibody. Biotinylated protein ladder
(Cell Signaling Technology, Danvers, MA) and MagicMark XP
marker (Invitrogen) were used for estimation of molecular
weights. For precise work Tris acetate gels were calibrated with
both HiMark molecular mass standards (Invitrogen) in the
50–500 kDa range, and biotinylated protein ladder for resultant
blots. Comparison of these calibrations allowed more reliable
estimation of the molecular weights of the larger complexes.
Two-dimensional Gel Electrophoresis—Samples containing
30–50 g of protein in two-dimensional gel electrophoresis
lysis buffer were prepared in rehydration buffer (final concen-
tration: 7 M urea, 2 M thiourea, 43mMdithiothreitol, 30mMTris
base, 1.2% CHAPS, 0.4% amidosulfobetaine-14 (a zwitterionic
detergent), 0.25% ampholytes) as described elsewhere (27) and
loaded onto 7-cm immobilized pH gradient (IPG) strips
(ImmobilineDryStrips, pH 3–10, GEHealthcare). First-dimen-
sion isoelectric focusing was performed at 20 °C using an IPG-
phor (GEHealthcare) and the following protocol: 30min at 0 V,
12 h at 50V, 4-h gradient to 2000V, and 6h at 4000V.Typically,
about 27 kV-h were accumulated during a run. Focused IPG
strips were stored at80 °C until used. Prior to second dimen-
sion SDS-PAGE, the strips were defrosted and then incubated
for 20 min first in equilibration buffer (6 M urea, 4% SDS, 30%
glycerol, 50 mM Tris-HCl (pH 6.8), trace bromphenol blue)
containing 25 mM dithiothreitol, and then in equilibration
buffer containing 360 mM acrylamide. Second dimension sepa-
ration was performed on NuPAGE 3–8% Tris acetate gels fol-
lowed by Western blotting. Protein pI values were estimated
from the pH gradient profile of the IPG strip provided by the
manufacturer. Theoretical pI values of the proteins were calcu-
lated with ProtParam, ExPASy.
EnzymaticDeglycosylation—Cell lysateswere incubatedwith
1% SDS at 60 °C for 20 min and then diluted 5-fold in 71 mM
sodiumphosphate, pH 7.2, containing 10mMEDTA, 1%Triton
X-100, 1% CHAPS, and 2% PIC. Proteins were deglycosylated
by adding 40 units/ml ofN-glycosidase F (PNGase, Roche) and
incubating the lysates overnight at 37 °C. Controls were treated
similarly, but without the PNGase.
Cell Surface Biotinylation—48h after transfection, cells were
placed on ice and rinsed twice with ice-cold PBS, pH 7.3, fol-
lowed by a rinse in borate buffer (in mM: 154 NaCl, 10 boric
acid, 7.2 KCl, 1.8 CaCl2, pH 9). Cells were gently agitated for 60
min at 4 °C in borate buffer containing 1.2 mg/ml of Sulfo-
NHS-LC-biotin (Pierce). The biotinylation reaction was
quenched by three 5-min washes in ice-cold PBS containing
100 mM glycine. Cells were then washed twice in PBS alone,
lysed in standard lysis buffer, and the protein concentration
determined as described above. Samples containing equal
amounts of protein were diluted in lysis buffer and incubated
with streptavidin beads (Qiagen) for 1 h at 4 °C under gentle
rotation. Supernatant was removed and beads were washed
twice in lysis buffer containing 0.5 M NaCl and three times in
PBS containing 0.05% Tween 20. Beads were then incubated in
sample buffer for 10 min at 40 °C to remove nonspecifically
boundproteins. The supernatantwas removed andbiotinylated
proteins were eluted by resuspending the beads in sample
buffer and heating them to 100 °C for 10 min.
Statistical Analysis—Values are given as mean  S.E. and,
unless otherwise stated, n represents the number of experi-
mental replicates. The difference between means was
assessed using two-tailed t tests, the level of significance for
all tests was set at p  0.05.
RESULTS
Cloning and Sequence Analysis of NKCC2 from Ferret Kidney
(fNKCC2)—We cloned the full-length open reading frame of
the fNKCC2 mRNA after determining its extreme ends as well
as a 251-bp 5-untranslated region and a 1228-bp 3-untrans-
lated region via RNA ligase-mediated RACE. Subsequent
sequencing of fNKCC2 constructs led to the identification of
four variants; fNKCC2A, -B, -F, and -AF (Fig. 1B). The pre-
dicted masses and pI values of fNKCC2 variants A, B, and F
(1100 amino acids) are 121 kDa and 7.7 (AF, 1132 amino acids,
124 kDa, pI 7.9). Sequence alignments with NKCC2s from dif-
ferent species show an overall identity of 95% to mouse, rat,
rabbit, and human NKCC2, and 99% to the predicted canine
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NKCC2 sequence. The amino acid sequence is 62% identical
(79% similar) to that of the closely related fNKCC1.
Sequence analysis (Fig. 1A) shows the presence of the con-
served regulatory domain in the N terminus including three
threonine residues (Thr100, Thr105, and Thr118) homologous to
the threonine residues phosphorylated in NKCC1 when acti-
vated by a reduction in cell chloride concentration or cell vol-
ume (12) and the residues (Ser91, Thr95, and Thr100) homolo-
gous to the threonine residues in NKCC1 phosphorylated in
vitro by SPAK or OSR1 (13). Putative N-glycosylation sites
Asn447 and Asn457 are present in the extracellular domain
between TM7 and -8 (28). Two possible SPAK/OSR1 binding
sites (15) are present in the N terminus (20RFQV23 and
57RFRI60) but the adjacent protein phosphatase 1 binding site
characteristic of NKCC1 (29) is absent.
fNKCC2 Expression in HEK-293 Cells—Our aim was to
express fNKCC2 variants in HEK-293 cells and detect the pro-
teins with an NKCC2-specific antibody. In our experience an
antibody raised to a fusion protein of the whole cytoplasmic N
terminus ofNKCC2 (anti-NKCC2, Table 1) gives themost con-
sistent results (see below). As HEK-293 cells express closely
related NKCC1, lysates from untransfected cells were used to
test for antibody cross-reactivity with endogenous NKCC1
(lane “” in all blots).NKCC1 is detected byN1 andT4 as bands
at154 kDa (NKCC1monomeric weight) and316 kDa (pos-
sible dimer), whereas phosphospecific R5 (30) mainly detects a
band at157 kDa, and occasionally a very weak band at315
kDa (Figs. 1 and 2 and Table 1).
After transfecting HEK-293 cells with fNKCC2A, -B, -F, and
-AF constructs, whole cell lysates were tested for the presence
of fNKCC2 using a variety of antibodies (Fig. 2, A and B, and
Table 1). Anti-NKCC2 detected strong bands at the expected
monomeric mass of glycosylated NKCC2, 134 kDa, in cells
transfected with fNKCC2A, -B, and -F, but not following trans-
fection with fNKCC2AF. It also detected bands at 104 kDa
with all four constructs (Fig. 2A), perhaps indicating that the
substantial unglycosylated or poorly glycosylated transporter is
produced in these transiently transfected cells. However, all
other NKCC2 antibodies except L224 (and in this case only
with large samples of A, B, or F) failed to detect the low molec-
FIGURE 1. Structural features of fNKCC2. A, regulatory region in the N ter-
minus of NKCC1 and NKCC2. Ferret (f) sequences are aligned with their
human (hu) counterparts. Known phosphorylation sites are marked by shad-
ing. Peptides used to raise phosphospecific antibodies R5 (30) and anti-
pNKCC (13) are shown by boxes. B, amino acid sequences of fNKCC2 variants
are encoded by alternative splicing of the 96-bp cassettes of exon 4. fNKCC2
sequences are alignedwith huNKCC2, with differences between the isoforms
indicated by shading. The second transmembrane domain is underlined.
TABLE 1
Detection of NKCC1 and NKCC2 by various antibodies
Molecular masses were estimated on scanned blots with TotalLab software. Molecular masses are mean S.D. (n 4 in most cases, values based on a single observation
indicated by) (aa, amino acid; hu human; f ferret; r rat).
Antibody Immunogen and targets in some equivalent proteins
Bands detected
HEK-293
Transfected with fNKCC2 varianta
Monomer molecular
mass High molecular mass
kDa
N1 N terminus, 2 peptides, huNKCC1, aa 71–84 and 235–255 317 11
154 3
T4 Last 310 aa of C terminus, huNKCC1, monoclonal 316 10 277 7 (A, B, F)
154 4 238 4 (A, B, AF)b
222 4 (F)b
R5 Phospho-peptide, huNKCC1, aa 208–223 (Thr(P)212, Thr(P)217) 157 5 135 5 (A, B, F) 279 7 (A, B, F)
(fNKCC1: Thr(P)204, Thr(P)209; fNKCC2: Thr(P)100, Thr(P)105)
Anti-pNKCC Phospho-peptide, huNKCC1, aa 198–217 (Thr(P)203, Thr(P)207,
Thr(P)212) (fNKCC1: Thr(P)195, Thr(P)199, Thr(P)204; fNKCC2:
Ser(P)91, Thr(P)95, Thr(P)104)
155 134 (A, B, F) 275 (A, B, F)
Anti-NKCC2 Entire cytoplasmic N terminus, huNKCC2 315c 134 4 (A, B, F) 273 8 (A, B, F)
104 4 (all) 233 4 (A, B, AF)b
220 5 (F)b
L224 N terminus, peptide, rNKCC2, aa 109–129 134 (A, B, F)d 275 4 (A, B, F)
235 (A, B, AF)d,222 (F)d
N2-Ct C terminus, peptide, fNKCC2, aa 1045–1018 279 1 (A, B, F)
237 2 (A, B, AF)d,222 (F)d
NKCC2 C terminus, rNKCC2, 15 aa peptide 277 1 (A, B, F)
234 2 (A, B, AF)b,222 (F)b
aOnly additional bands tabulated also have bands found in HEK-293 controls.
b Present in most blots.
c Cross-reactivity seen if blots are overloaded and overexposed.
d Present in minority of blots and only after long exposure times.
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ular weight forms of fNKCC2 (Fig. 2A and Table 1) despite the
epitopes being present with, at most, only minor modification.
On the other hand these sameNKCC2 antibodies detected high
molecular weight forms of expressed fNKCC2 (Fig. 2B and
Table 1). Interestingly, the phospho-specific antibody R5
detected additional bands at both135 (Fig. 2A) and279 kDa
(Fig. 2B) in NKCC2A, -B, and -F (but not -AF) transfected cells,
and a phospho-specific antibody raised to an adjacent epitope
(anti-pNKCC; Fig. 1A and Table 1) showed the same band
pattern.
As no significant differences were seen in the molecular
weights of the principal bands detected by the different anti-
bodies, data can be combined. Transfection of HEK-293 cells
with fNKCC2A, -B, or -F causes the appearance of additional
bands at (average molecular masses) 104, 134, and 275 kDa. A
band that appears at 235 kDa in fNKCC2Aor -B runs at 222 kDa
in fNKCC2F. Expression of fNKCC2AF causes bands to appear
at 104 and 235 kDa. Normally, anti-NKCC2 did not detect
endogenous NKCC1. However, with very long exposures (for
instance, when being used to detect variant -AF), a faint band at
the characteristic weight ofNKCC1 could be detected (Fig. 6A).
In contrast, we found no evidence for cross-reaction between
N1 and fNKCC2 even when expressed at high levels. In addi-
tion, independent of the antibody used, we generally found that
for the same protein load, lysates of cells transiently transfected
with fNKCC2B gave approximately twice as much signal as
those transfected with fNKCC2A, which in turn was twice as
much as with fNKCC2F.
To see if difficulties in detecting the monomeric forms of
fNKCC2weremerely a problemof the expression systemor the
species used, we probed crudemembrane preparations of ferret
and rat kidney with the same set of antibodies, using lysates of
HEK-293 cells transfected with fNKCC2A for comparison (Fig.
2C). Again, T4, L224, and N2-Ct detected strong high molecu-
lar weight bands but also detected at least one band at the
approximate monomeric weight of NKCC2. A greater propor-
tion of NKCC2 was found in high molecular weight forms in
ferret compared with rat samples. Interestingly, N1 detected
bands at the same molecular weights (lower than NKCC1 in
other tissues), suggesting kidney NKCC1 and NKCC2 migrate
similarly on SDS-polyacrylamide gels.
fNKCC2 Is Heavily Glycosylated and Trafficked to the Cell
Surface—To be functional both NKCC1 and NKCC2 are heav-
ily glycosylated on two asparagine residues in the extracellular
loop between TM7 and -8 (1, 28). As these residues are con-
served in fNKCC2 (Asn447 and Asn457) we examined the effects
of treating cell lysates with PNGase (Fig. 3A). The right-hand
panels of Fig. 3A show that the apparent molecular mass of
endogenous NKCC1 falls by 30 kDa when deglycosylated.
The fall is similar whether the cells were transfected with
fNKCC2A, -B, or -F. The apparent mass of monomeric
fNKCC2 (left-hand panel, Fig. 3A) falls by about 35 kDa (to99
kDa) supporting the idea that the 104-kDa band represents
poorly or unglycosylated fNKCC2. Although similar results
were obtained with the higher molecular weight forms of
NKCC1, the decrease in apparent molecular mass for NKCC2
was larger (45 kDa, data not shown), suggesting that the 275-
kDa bands represent complex glycosylated forms, and the 235
FIGURE 2. Interaction of fNKCC2 variants with antibodies. A and B, whole
cell lysates (7 g) of untransfected () HEK-293 cells and cells transfected
with fNKCC2A, -B, -F, and -AF; and C, crude membranes (adjusted to allow
similar levels of detection) from ferret (FK) and rat (RK) kidneys, were sub-
jected to SDS-PAGE and immunoblotted with antibodies (see Table 1 for
details) against NKCC1 (N1), NKCC2 (anti-NKCC2, L224, andN2-Ct), NKCC1 and
2 (T4), and phoshpo-NKCC1 and 2 (R5). Molecular mass markers (in kDa) are
shownon the leftandNKCC isoformson the right.A,monomericNKCC.B, high
molecular weight bands. The molecular weight calibration in the top and
bottom panels are identical. C, comparison of NKCCs in kidney and fNKCC2A-
transfected HEK-293 cells.
FIGURE 3. fNKCC2 glycosylation and appearance in the cell surface.
A, whole cell lysates from HEK-293 cells transfected with fNKCC2A, -B, and -F
were treated with () or without () PNGase F, subjected to SDS-PAGE, and
immunoblotted with anti-NKCC2 (left panel) and re-probed with T4 (right
panel). Exposure time was increased to detect fNKCC2F (shown by vertical
line). B, detection of surface proteins. 48 h after transfection HEK-293 cells
were surface biotinylated with Sulfo-NHS-LC-biotin. Biotinylated proteins
were precipitated from cell lysates with streptavidin beads, eluted, run on
SDS-PAGE, and immunoblotted with anti-NKCC2 (left panels) and re-probed
with N1 to detect endogenous NKCC1 (right panels). Twice as much protein
was loaded and longer exposure times were used to detect surface proteins
comparedwith total proteins. Molecular massmarkers (in kDa) are indicated.
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(or 222)-kDa bands represent poorly or unglycosylated forms.
Comparison with Fig. 2 indicates that only the complex-glyco-
sylated forms (134 and 275 kDa) can be phosphorylated and
detected by phospho-specific antibodies like R5.
To see if the fNKCC2 isoforms were properly trafficked to
the plasmamembranewe biotinylated surface proteins by reac-
tion with sulfo-NHS-LC-biotin and precipitated biotinylated
proteins with streptavidin beads. Endogenous NKCC1 and
exogenous fNKCC2 were then identified by Western blotting
with specific antibodies (Fig. 3B). Monomeric and high (possi-
bly dimeric) molecular weight forms of both NKCC1 and
fNKCC2 could be biotinylated at the cell surface suggesting
they are trafficked to the plasma membrane. There was no dif-
ference between fNKCC2A, -B, and -F and, as has been
described before (7), only the complex-glycosylated forms
(bands at 134 and 275 kDa, but not at 104, 235, or 222 kDa, Fig.
3B) of the cotransporter appeared in the biotinylated fraction.
As larger sample sizes and longer exposure times were required
to detect the transporters in the biotinylated compared with
whole cell samples it appears that only a small fraction of total
NKCC1 or fNKCC2 is in the surface membrane and can be
biotinylated as suggested previously (31, 32).
Expressed fNKCC2 Is Functional—After confirming fNKCC2
was expressed, complex glycosylated, and trafficked to the
plasma membrane, we next tested if it was functional by mea-
suring the bumetanide-sensitive uptake of 86Rb under two con-
ditions. First, after a 1-h incubation in an isotonic medium to
assess basal cotransporter activity, and second, after 1 h in a
hypotonic/low-chloride medium to activate the cotransporter.
The fluxes themselves were measured in identical media.
Transfection of HEK-293 cells with empty vector had no effect
on fluxes under either condition (Fig. 4). Robust additional
bumetanide-sensitive 86Rb uptakes were observed in cells
transfected with fNKCC2A, -B, and -F incubated under iso-
tonic conditions. These basal fluxes showed the largest propor-
tional increase following transfection. Comparedwith untrans-
fected cells, basal activity was increased by 80%with fNKCC2A,
140%with fNKCC2B, and 50%with fNKCC2F (Fig. 4). Interest-
ingly, this roughly follows the observed relative expression lev-
els of fNKCC2A, -B, and -F in HEK-293 cells (Fig. 2). Even
though these increases in 86Rb uptake are highly significant
(p  0.005), 30–40% of bumetanide-sensitive 86Rb uptakes
probably occur through the endogenous NKCC1 of the HEK
whose expression level and phosphorylation state (Fig. 2A) are
not affected by the expression of any fNKCC2 variant. Bumet-
anide-resistant 86Rb fluxes were not significantly affected by
transfecting HEK-293 cells with fNKCC2 variants, nor were
they affected by incubating these cells in a hypotonic/low chlo-
ride medium (103.6 2.7% control, n 7).
The highest fluxes were measured following incubation in
hypotonic/low-chloride medium to stimulate NKCC2 (18).
However, transfecting cells with fNKCC2A and -B caused a
smaller relative increase in bumetanide-sensitive 86Rb uptake
under these conditions (40% for fNKCC2A and 80% for
fNKCC2B) comparedwith results obtained under isotonic con-
ditions, although the increase for fNKCC2F (50%) was similar
to that under isotonic conditions. Although 86Rb uptakes were
significantly higher in transfected cells, this result shows that
pre-treatment with hypotonic/low-chloride medium causes
greater activation of endogenous NKCC1 than transfected
fNKCC2. In all cases, stimulation by hypertonic/low-chloride
pre-treatment was accompanied by an increase in phosphory-
lation of the regulatory threonine residues in the N termini of
the transporters as detected by R5 (Fig. 4), whereas endogenous
NKCC1 and fNKCC2 protein levels remained constant (Fig. 4).
Stable Expression of fNKCC2—To date, the only report of a
cell line stably expressingNKCC2 concerns a NKCC1–NKCC2
chimera in which the first 104 amino acids of rabbit NKCC2A
had been replaced by the equivalent residues of humanNKCC1
(6). After observing functional fNKCC2 expression in transient
transfected cells, we also tried to create stable cell lines. Follow-
ing selection for geneticin resistance, cells were tested for the
presence of the fNKCC2 protein. As shown in Fig. 5A, a strong
NKCC2 signal was detected in cells transfectedwith fNKCC2A,
whereas those from cells expressing fNKCC2B and -F were
much weaker, and none was seen in cells transfected with
empty vector. The strength of the NKCC1 signal was similar
with all variants (Fig. 5A, bottom panel) indicating that the sta-
ble expression of fNKCC2 does not affect the total level of
NKCC1 in these cells. Functional expression of fNKCC2 was
assessed by measuring bumetanide-sensitive 86Rb uptake in
cells under isotonic conditions or following incubation in hypo-
tonic/low-chloride medium. Stable expression of the empty
FIGURE 4. Functional expression of fNKCC2 variants in HEK-293 cells.
HEK-293 cells were transfected with empty vector (pcDNA) or fNKCC2 con-
structs (A, B, and F) andgrown to confluence. 2–3 days post-transfection, 86Rb
uptake was assessed following preincubation in isotonic (basal conditions,
open bars) or hypotonic/low-chloride medium (filled bars). In each experi-
ment, 86Rb uptakes were normalized to the 86Rb uptake in untransfected
HEK-293 cells under basal conditions and shown as mean  S.E. Uptake (in
nanomole mg protein1 min1) under basal conditions were 4.0 0.4 (n
19) and in specific experiments were: 4.7  0.8 (versus pcDNA), 4.2  0.6
(versus fNKCC2A), 4.1 0.5 (versus fNKCC2B), and 3.6 0.5 (versus fNKCC2F).
Transfection of HEK-293 cells increasedbumetanide-sensitive 86Rb uptake by
80 17% (-A, n 9), 144 26% (-B; n 10), and 53 13% (-F; n 10) under
basal conditions andby 39 10% (-A,n 5), 82 6% (-B,n 5), and 50 6%
(-F, n 5) following incubation in a hypotonic/low-chloride medium. *, p
0.05; **, p 0.005 comparedwith HEK-293 uptake under the same condition.
Uptakes in the presence of 10 M bumetanide were similar under all condi-
tions. Thus between 14 and 35% total uptake was bumetanide-insensitive
depending on whether the cells had been incubated in hypotonic/low chlo-
ride or isotonic media. Expression and phosphorylation of NKCC proteins
were assessed by immunoblot analysis using the antibodies indicated.
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vector did not significantly affect fluxes under these conditions
(relative to control HEK-293: 110  7% (isotonic, n  7) and
103  8% (hypotonic/low-chloride, n  5)). Stable expression
of fNKCC2A caused a significant increase in 86Rb uptake under
both conditions (Fig. 5B) with uptake increased by 145 and
72% following incubation in isotonic or hypotonic/low-chlo-
ride media, respectively. As with cells transiently expressing
fNKCC2A, activationwas less following preincubation in hypo-
tonic/low-chloridemedium. In contrast, no significant changes
in 86Rb uptakes were found in cells stably expressing fNKCC2B
or -F under either condition (data not shown). This is most
likely due to low expression of these fNKCC2 variants as dem-
onstrated by the Western blots (Fig. 5A).
fNKCC2AF Does Not Affect Transport by fNKCC2A—
NKCC2AF has only previously been expressed and character-
ized in oocytes (5, 22), and we now demonstrate that it can also
be transiently expressed in HEK-293 cells. Fig. 2,A and B (lanes
AF), show that anti-NKCC2 detects the 104- and 235-kDa
bands and T4 the 235-kDa band in HEK-293 cells expressing
fNKCC2AF. As this pattern is characteristic of poorly glyco-
sylated forms of otherNKCC2 variants (Fig. 3A) we suggest that
fNKCC2AF is not properly glycosylated by the cell. This view is
supported by the finding that treatment of lysates of cells trans-
fected with fNKCC2AF with PNGase did not cause any signif-
icant change in the molecular weight of bands detected with
anti-NKCC2 (Fig. 6A, left), whereas the expected reduction of
30 kDa was seen in bands detected with N1 (NKCC1, Fig. 6A,
right).
Expressed fNKCC2AF does not appear to be trafficked to
the cell surface. Proteins with extracellular domains in
fNKCC2AF-expressing cells were biotinylated and then iso-
lated using streptavidin beads. When subjected to Western
blotting these proteins did not reactwith anti-NKCC2 although
they did with N1 (NKCC1) (Fig. 6B). Both NKCC1 and
fNKCC2AF were detected in whole cell lysates from these cells
(Fig. 6B). In addition, transient transfection of HEK-293 cells
with fNKCC2AF did not affect bumetanide-sensitive 86Rb
uptake measured under basal conditions or following preincu-
bation in an hypotonic/low-chloride medium (Fig. 6C).
It has been reported that expression of NKCC2AF in oocytes
has a dominant-negative effect on coexpressed NKCC2A or -F
(22). To see whether this also occurs in the HEK-293 cell
expression system, we transfected HEK-293 cells stably
expressing fNKCC2A with fNKCC2AF and measured the
resulting bumetanide-sensitive 86Rb uptakes under basal con-
ditions and following preincubation in hypotonic/low-chloride
medium. Fig. 6D shows that 86Rb uptakes by cells stably
expressing fNKCC2Awere not affected by the co-expression of
fNKCC2AF under either condition. There is no evidence for a
dominant-negative effect in the HEK-293 cell system.
Two-dimensional Electrophoresis of fNKCC2 and NKCC1—
NKCC1 and NKCC2 may have similar molecular weights as
determined by SDS-PAGE (especially if unglycosylated forms
FIGURE 5. Stable expression of fNKCC2. A, HEK-293 cells were transfected
with pCI-fNKCC2 constructs (A, B, and F) or empty vector () and selected for
geneticin resistance. Equal amounts of whole cell lysates were subjected to
SDS-PAGE, immunoblotted with anti-NKCC2 (top panel), and re-probed with
N1 (bottom panel). Molecular size markers (in kDa) are indicated. B, HEK-293
cells either untransfected, or stably expressing fNKCC2A, were grown to con-
fluence, and 86Rb uptake was assessed following incubation of cells in iso-
tonic (basal conditions, open bars) or hypotonic/low-chloride (filled bars)
medium.Bumetanide-sensitive 86Rbuptakes are shownasmeanS.E. Stable
expression of fNKCC2A increased 86Rb uptake by 145  30% (n  17, p 
0.00028) in basal conditions and by 72 10% (n 16, p 0.00013) following
incubation in hypotonic/low-chloridemedium. Expression and phosphoryla-
tion of NKCC proteins were assessed using the antibodies indicated.
FIGURE6. fNKCC2AF: glycosylation, surfaceexpression, and 86Rbuptake.
A, cell lysates from HEK-293 cells transfected with fNKCC2AF were incubated
with () or without () PNGase F, subjected to SDS-PAGE, immunoblotted
with anti-NKCC2 (left panel), and re-probed with N1 antibody (right panel).
Molecular sizemarkers (in kDa) and cross-reaction of anti-NKCC2with NKCC1
(*) are indicated on the left and NKCC2AF is marked by an arrow on the right.
B, 48 h after transfection with fNKCC2AF HEK-293 cells were surface bio-
tinylated with Sulfo-NHS-LC-biotin. Biotinylated proteins were precipi-
tated from cell lysates with streptavidin beads, run on SDS-PAGE, immu-
noblotted with anti-NKCC2 (left), and re-probed with N1 to detect
endogenous NKCC1 (right). Twice as much protein was loaded and longer
exposure times were used to detect surface proteins (S) compared with
total proteins (T). C, untransfected (HEK) and fNKCC2AF-transfected (AF)
HEK-293 cells, and D, stable fNKCC2A (A) and stable fNKCC2A cells co-
expressing fNKCC2AF (AAF) were grown to confluence (2–3 days). 86Rb
uptake was assessed following incubation of cells in isotonic (basal con-
ditions, open bars) or hypotonic/low-chloride (filled bars) medium. Bumet-
anide-sensitive 86Rb uptakes are shown as mean  S.E. Expression of
fNKCC2AF has no significant (n.s.) effect on 86Rb uptakes by HEK-293 cells
(C) (n  4) or HEK-293 cells stably expressing fNKCC2A (D) (n  3).
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are present) and identification viaWestern blotting can be hin-
dered by cross-reactions of available antibodies. However, as
their theoretical pI values differ widely (fNKCC1, pI  6.1;
fNKCC2, pI 7.7), better discrimination between the isoforms
might be achieved using two-dimensional gel electrophoresis.
Whole cell lysates of HEK-293 cells and HEK-293 cells trans-
fected with fNKCC2Awere subjected to isoelectric focusing on
immobilized pH gradients as the first dimension, and SDS-
PAGE as the second. Endogenous NKCC1 and fNKCC2Awere
found as high-molecular mass (300 kDa) complexes with
broad overlapping pI values (Fig. 7) ranging from pH 5.1 to 6.1
for NKCC1 and pH 5.4 to 6.4 for fNKCC2A. However, the
majority of NKCC1 was detected between pH 5.25 and 5.65,
whereas the majority of fNKCC2A appeared between pH 5.5
and 5.95, revealing a small but distinct difference in the pI
ranges of the two isoforms. Post-translational modifications
canhave a strong influence onprotein pI and both glycosylation
and phosphorylation would be expected to move the pI values
in the acidic direction as observed. However, we were surprised
that the large difference in (theoretical) pI values was so greatly
attenuated. This was mainly due to the pI of fNKCC2A, which
had becomemuchmore acidic than expected.We repeated the
experiment with samples containing fNKCC2AF as this is nei-
ther glycosylated (Fig. 6A), nor phosphorylated in the N termi-
nus regulatory domain (Fig. 2, A and B). Anti-NKCC2 detected
two distinct signals. One signal, probably representing
fNKCC2AF itself, stretched from pH 6.9 to 7.7 with the strong-
est signal between pH 7.35 and 7.7 and a second signal was
detected from pH 5.3 to 5.8. The latter corresponds to themost
intense area of the N1 signal (Fig. 7, fourth panel) and is most
likely caused by cross-reaction of anti-NKCC2 with NKCC1
when long exposures are used (see Fig. 6A). Thus, the observed
pI for fNKCC2AF is much closer to its theoretical value than
that of fNKCC2A demonstrating the extent of post-transla-
tional modifications on fNKCC2A. No differences could be
detected in the pI values of NKCC1 in untransfected HEK-293
cells (Fig. 7, bottom) and in those expressing either fNKCC2A
or -AFmaking it unlikely thatNKCC1 forms heterodimerswith
fNKCC2.
DISCUSSION
To study the regulation of NKCC2 it is important that
unmodified forms of NKCC2 be expressed in a mammalian
system. Small changes in the structure of NKCC2, for instance,
phosphorylation or a change in the hydrophobicity of just a few
residues, can have a large impact on function, altering activity,
trafficking, or propensity to bind regulators. The addition of
small tags that permit expression (as was necessary in the past)
may also alter its responses to stimuli. In this paper we demon-
strate for the first time the functional expression of the major
NKCC2 variants, fNKCC2A, -B, and -F in mammalian HEK-293
cells.We used native proteins that had not been tagged ormod-
ified in any other way. Our results also help explain why func-
tional expression of NKCC2 was so problematic in the past. It
resulted from three factors: poor reactivity of expressed
NKCC2 with available antibodies, the small size of fluxes
through transfected NKCC2, and the expectation that a reduc-
tion in cell chloride concentration would help reveal the pres-
ence of the transporter.
Our studies show that expressed fNKCC2A, -B, and -F
become glycosylated (Fig. 3) and can be phosphorylated in the
regulatory threonine domain in their N termini (see Figs. 2 and
4). Unglycosylated forms are not phosphorylated (Fig. 2), nor
do they appear in the plasma membrane (see Figs. 3 and 6).
Bumetanide-sensitive fluxes in transfected cells are about twice
the size of fluxes through the endogenous (NKCC1) system in
control (untransfected, mock-transfected) cells under basal
conditions (see Fig. 4). With transient transfection the magni-
tudes of these fluxes follow the order B	 A	 F, which follow
the intensities of expressed fNKCC2 protein (see Fig. 2). Fluxes
in transfected cells are stimulatedmore than 2-fold by preincu-
bating them in hypotonic/low-chloride medium and are sub-
stantially greater than fluxes in untransfected HEK-293 cells
under the same conditions (Fig. 4). As this preincubation causes
maximal activation of endogenous NKCC1 it is likely that the
additional fluxes seen in transfected cells are mediated by
NKCC2 and are not due to stimulation of endogenous trans-
porters. It also seems unlikely that transfected fNKCC2 takes
over the role of endogenous NKCC1 as the expression of
fNKCC2 affects neither the levels nor phosphorylation status of
endogenous NKCC1 (Fig. 4).
Stable transfections with fNKCC2A, -B, and -F were also
achieved. High levels of transfected proteins were obtained for
fNKCC2A but the levels weremuch lower for fNKCC2B and -F
(Fig. 5). We show that fNKCC2A is functional in stable cells
with bumetanide-sensitive 86Rb fluxes that are larger than in
transiently transfected cells (12.9 1.4 (n 19) versus 6.9 1.3
(n 8) nmol mg protein1 min1, respectively, Figs. 4 and 5).
However, although additional fluxes could be detected in stable
fNKCC2B and -F cells these did not reach statistical signifi-
cance. This was not surprising given the low level of transfected
proteins and the level of background, NKCC1-mediated fluxes.
Others have had a similar experience with the only other
NKCC2 construct that has been successfully stably expressed in
FIGURE 7. Comparison of NKCC1 and fNKCC2 by two-dimensional gel
electrophoresis. Whole cell lysates from untransfected, fNKCC2AF-trans-
fected HEK-293 cells, and cells stably expressing fNKCC2Awere separated on
7-cm Immobiline DryStrips pH 3–10, the strips were subjected to SDS-PAGE
followed by immunoblotting with anti-NKCC2 and re-probing with N1 anti-
body. Representative blots are shown. The molecular masses of complexes
exceeded 300 kDa. The pH gradient across the strip, calculated according to
information provided by the manufacturer, is given at the top.
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mammalian cells, an NKCC1–NKCC2A chimera (6). This con-
struct produced robust fluxes, whereas similar chimeras con-
taining NKCC2B or -F did not. It is striking that very small
variations in the TM2 structure of NKCC2 and intracellular
loop 1 have such a large impact on the ability of HEK-293 cells
to stably express the transporter. This might be due to the dif-
ferences in ion affinities and the effects these have on transport
under culture conditions. Alternatively, they may affect inter-
actions between transporter and vital regulatory molecules.
Some of these problems might be overcome by using an induc-
ible gene expression system to allow the establishment of stable
cell lines before expression of the transporters.
We also expressed fNKCC2AF in HEK-293 cells (Fig. 6).
Western blotting showed that although the protein was readily
detected it was not surface biotinylated, nor did it become gly-
cosylated or phosphorylated in the N terminus, a view sup-
ported by two-dimensional gel electrophoresis experiments
(Fig. 7), which also suggested that fNKCC2AF exists in the cell
as a high molecular weight complex (possible dimer). Bumet-
anide-sensitive 86Rb fluxes in these cells were identical to fluxes
in untransfected HEK-293 cells. As we find fNKCC2AF is not
trafficked to the cell surface our uptake results do not indicate
whether fNKCC2AF can transport ions, although studies on
Xenopus oocytes suggest it does not (22). Importantly, the tran-
sient expression of fNKCC2AF had no effect on the bumet-
anide-sensitive 86Rb fluxes in cells stably expressing fNKCC2A
under basal conditions or after preincubation in hypotonic/
low-chloride medium. Together, these experiments suggest
that fNKCC2AF does not affect either the trafficking of, or
fluxes through, endogenous NKCC1, or stably expressed
fNKCC2A. No evidence could be found for a dominant-nega-
tive effect for this variant in themammalian expression system.
This contrasts with the situation in Xenopus oocytes where
NKCC2AF (from shark) was detected in the plasmamembrane
and reduced flux through co-expressed NKCC2A or -F (22).
This is reminiscent of the contrasting ways in which Xenopus
oocytes andmammalian cells process cystic fibrosis transmem-
brane conductance regulator (CFTR) mutants (33) or NKCC2
mutants that cause Bartter syndrome. In the latter it was ini-
tially shown that Bartter syndromemutants ofNKCC2 could be
trafficked to themembranes ofXenopus oocytes, although they
remained non-functional (34). However, more recently it has
been shown that in mammalian cells some Bartter syndrome
mutants never leave the endoplasmic reticulum due to the
absence of a trafficking signal in their C terminus (35). So, even
though many proteins are trafficked similarly in Xenopus
oocytes and mammalian cells, it is clear that some mutant
transport proteins reach the surface of Xenopus oocytes,
whereas they are not trafficked to the surface of mammalian
cells. It is also possible that the NKCC2AF protein has a role at
the cell surface in shark kidney (and is trafficked in Xenopus
oocytes) that has been lost inmammals perhaps coincidingwith
the emergence of NKCC2B (5). The role of NKCC2AF in the
mammalian kidney remains a mystery. Even though significant
levels of NKCC2AF mRNA are present (2, 23), it is not known
whether the protein is expressed or reaches the plasma mem-
brane as current antibodies do not have the required selectivity.
One possibility is that themRNA is produced as a consequence
of pre-mRNA splicing during regulation of expression of
NKCC2A and -F.
Cross-linking studies of human NKCC2 expressed in Xeno-
pus oocytes suggest that NKCC2 exists as a dimer in the mem-
brane (36). Without making any attempt to stabilize dimers,
Western blots (Fig. 2B) prepared from cells expressing all vari-
ants of fNKCC2 show a significant portion of the protein run-
ning at molecular weights consistent with the formation of
dimers (Figs. 2, 3, and 5). In addition, the vast majority of
fNKCC2A and -AF run at a high molecular weight on two-
dimensional gel electrophoresis (Fig. 7). Again the weights are
consistent with dimer formation, although we cannot rule out
at this stage that a different protein is the binding partner(s).
NKCC1 can also form dimers (37, 38) and the interaction
appears to involve domains in the C terminus if the protein (39,
40), a region that is highly conserved in NKCC2. The question
therefore arises whether NKCC1 can form heterodimers with
NKCC2. Experiments based on yeast two-hybrid studies sug-
gest they can (22), whereas pulldown assays using chimeric pro-
teins suggest they do not (40). The regions in the C termini of
NKCC2 involved in dimer formation are common to all vari-
ants (22). Our two-dimensional gel electrophoresis experi-
ments show that co-expression of fNKCC2A or -AF with
NKCC1 has no effect on the distribution of NKCC1 along a pH
gradient (Fig. 7). Had there been significant NKCC1–fNKCC2
heterodimer formation the high molecular weight complexes
detected by N1 should have moved in the alkaline direction
(especially with fNKCC2AF). Our flux studies further support
the notion that the isoforms do not interact. Expression of non-
functional NKCC1 constructs in HEK-293 cells often substan-
tially inhibit the activity of endogenous NKCC1 (12, 26). We
have yet to find an NKCC2 construct whose expression affects
endogenous NKCC1 activity. If the dominant-negative effect is
mediated by dimer formation then it is unlikely that NKCC1
forms heterodimers with NKCC2. Perhaps the motifs that tar-
get the different isoforms to the apical or basolateral mem-
branes also prevent such interactions.
A key issue in these studies was the choice of antibody to
detect NKCC2. Initially we used antibodies raised to short pep-
tides in the C or N termini of the transporter (Table 1). These
antibodies detected bands at a high molecular mass (275 kDa),
well above the expected monomeric mass (Fig. 2). Only L224
detected bands at the monomeric weight, and those were very
weak. T4, amonoclonal antibody raised to a large section of the
C terminus of NKCC1 and reacting with both NKCC isoforms,
also only detected the high molecular weight forms. However,
we found that phospho-specific antibodies were raised to
epitopes in the N terminus of NKCC1 and conserved between
NKCC isoforms, detected strong bands at the monomeric
weight ofNKCC2. Thusmonomeric and highmolecularweight
forms of NKCC2 appear to have different structures that affect
access of antibodies to their epitopes. These structural differ-
ences are maintained even though proteins have been treated
with SDS sample buffer. Thus the transporter, expressed in
HEK-293 cells, appears in amore closed state whenmonomeric
and in a more open state when in high molecular weight forms.
However, these same antibodies do detect some monomeric
NKCC2 in kidney lysates (but far more high molecular weight
Functional Expression of NKCC2 inMammalian Cells
35356 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 51•DECEMBER 18, 2009
 by guest on June 14, 2013http://www.jbc.org/Downloaded from 
complexes). This may be due to the very high expression levels
ormay indicate thatNKCC2 adopts a different conformation in
its native environment. If true, this might also explain why the
transporter is highly active in the kidney yet produces relatively
small fluxes in transfected cells (Figs. 4 and 5). Reliable identi-
fication ofNKCC2 becomes simplifiedwith the development of
a polyclonal antibody to the wholeN terminus of NKCC2 (anti-
NKCC2, Alessi, Dundee). This antibody detects all fNKCC2
variants at the expected monomeric weight as well as the high
molecular weight forms. A slight drawback is its weak cross-
reactivitywithNKCC1,whichmust be taken into accountwhen
NKCC1 is overexpressed or when long exposures are used for
detection. Anti-NKCC2 also detected strongmonomeric bands
in kidney lysates (Fig. 2C). It appears that antipeptide antibod-
ies andmonoclonal T4, all of which bind to small regions in the
N and C termini of NKCC2, react almost exclusively with the
highmolecular weight forms despite the presence of significant
amounts of monomers in the samples. Polyclonals to large
domains seem more effective at recognizing the monomers. It
was also noted that PNGase-treated fNKCC2migrates substan-
tially faster on SDS-PAGE than expected (99 versus 121 kDa).
This is not uncommon for membrane proteins as their SDS
binding capacity can change with protein folding (41).
Relatively small bumetanide-sensitive 86Rb fluxes were mea-
sured in HEK-293 cells transfected with fNKCC2 variants
under basal conditions. A similar phenomenon occurs with
cells stably expressing NKCC1. Here fluxes are barely larger
than in untransfected controls, suggesting transfected cells
switch off the expressed transporter. The presence of the func-
tional transporter is only revealed if it can be reactivated. This
can be achieved for NKCC1 by preincubating cells in a hypo-
tonic/low-chloride medium that increases fluxes manyfold
above background (6). However, this protocol only increases
fluxes 2–3-fold in cells expressing fNKCC2, and background
fluxes are stimulated to a greater extent. Our data thus suggest
that NKCC2 is less responsive to changes in cell chloride con-
centration than NKCC1, and that the maneuver that helps
reveal the presence of transfected NKCC1 in fact obscures the
presence of transfected NKCC2. A more effective means of
activating this transporter needs to be devised bearing in mind
the possibility that HEK-293 cells may not express a necessary
cofactor that is present in the native thick ascending limb of the
Henle loop. Our work suggests that little is to be gained from
increasing still further the phosphorylation of regulatory
domain threonines and maneuvers that increase cell surface
expression may provide a way forward. Although Xenopus oo-
cytes prove useful for studying the biophysical properties of
NKCC2, discrepancies in the behavior of NKCC2AF in Xeno-
pus oocytes and HEK-293 cells highlight the importance of
studying certain aspects of the regulation of NKCC2, especially
those involvingNKCC2 trafficking, in amammalian expression
system. The availability of stableNKCC2 cell lines should prove
a useful tool in this endeavor.
Acknowledgments—We thank Professors D. Alessi, B. Forbush, and
M.Knepper for the generous gifts of antibodies, ProfessorD. Alessi and
Dr. Ciaran Richardson for helpful discussions.
REFERENCES
1. Gamba, G. (2005) Physiol. Rev. 85, 423–493
2. Castrop, H., and Schnermann, J. (2008) Am. J. Physiol. Renal Physiol. 295,
F859–F866
3. Flatman, P. W. (2007) Clin. Sci. 112, 203–216
4. Payne, J. A., and Forbush, B., 3rd (1994) Proc. Natl. Acad. Sci. U.S.A. 91,
4544–4548
5. Gagnon, E., Forbush, B., Flemmer, A. W., Gime´nez, I., Caron, L., and
Isenring, P. (2002) Am. J. Physiol. Renal Physiol. 283, F1046–F1055
6. Isenring, P., Jacoby, S. C., Payne, J. A., and Forbush, B., 3rd (1998) J. Biol.
Chem. 273, 11295–11301
7. Benziane, B., Demaretz, S., Defontaine, N., Zaarour, N., Cheval, L.,
Bourgeois, S., Klein, C., Froissart, M., Blanchard, A., Paillard, M.,
Gamba, G., Houillier, P., and Laghmani, K. (2007) J. Biol. Chem. 282,
33817–33830
8. Gime´nez, I., Isenring, P., and Forbush, B. (2002) J. Biol. Chem. 277,
8767–8770
9. Plata, C., Meade, P., Vazquez, N., Hebert, S. C., and Gamba, G. (2002)
J. Biol. Chem. 277, 11004–11012
10. Gagnon, E., Bergeron, M. J., Daigle, N. D., Lefoll, M. H., and Isenring, P.
(2005) J. Biol. Chem. 280, 32555–32563
11. Gime´nez, I., and Forbush, B. (2007) J. Biol. Chem. 282, 6540–6547
12. Darman, R. B., and Forbush, B. (2002) J. Biol. Chem. 277, 37542–37550
13. Vitari, A. C., Thastrup, J., Rafiqi, F. H., Deak, M., Morrice, N. A., Karlsson,
H. K., and Alessi, D. R. (2006) Biochem. J. 397, 223–231
14. Lytle, C., and Forbush, B., 3rd (1996) Am. J. Physiol. 270, C437–C448
15. Piechotta, K., Lu, J., and Delpire, E. (2002) J. Biol. Chem. 277,
50812–50819
16. Dowd, B. F., and Forbush, B. (2003) J. Biol. Chem. 278, 27347–27353
17. Gime´nez, I., and Forbush, B. (2005) Am. J. Physiol. Renal Physiol. 289,
F1341–F1345
18. Ponce-Coria, J., San-Cristobal, P., Kahle, K. T., Vazquez, N., Pacheco-
Alvarez, D., de Los Heros, P., Jua´rez, P., Mun˜oz, E., Michel, G., Bobadilla,
N. A., Gimenez, I., Lifton, R. P., Hebert, S. C., and Gamba, G. (2008) Proc.
Natl. Acad. Sci. U.S.A. 105, 8458–8463
19. Gime´nez, I., and Forbush, B. (2003) J. Biol. Chem. 278, 26946–26951
20. Gamba, G., Miyanoshita, A., Lombardi, M., Lytton, J., Lee,W. S., Hediger,
M. A., and Hebert, S. C. (1994) J. Biol. Chem. 269, 17713–17722
21. Igarashi, P., VandenHeuvel, G. B., Payne, J. A., and Forbush, B., 3rd (1995)
Am. J. Physiol. 269, F405–F418
22. Brunet, G.M., Gagnon, E., Simard, C. F., Daigle, N. D., Caron, L., Noe¨l,M.,
Lefoll, M. H., Bergeron, M. J., and Isenring, P. (2005) J. Gen. Physiol. 126,
325–337
23. Yang, T., Huang, Y. G., Singh, I., Schnermann, J., and Briggs, J. P. (1996)
Am. J. Physiol. 271, F931–F939
24. Oppermann, M., Mizel, D., Huang, G., Li, C., Deng, C., Theilig, F., Bach-
mann, S., Briggs, J., Schnermann, J., and Castrop, H. (2006) J. Am. Soc.
Nephrol. 17, 2143–2152
25. Flatman, P. W. (2002) Biochim. Biophys. Acta 1566, 140–151
26. Isenring, P., and Forbush, B., 3rd (1997) J. Biol. Chem. 272, 24556–24562
27. Khoudoli, G. A., Porter, I. M., Blow, J. J., and Swedlow, J. R. (2004) Pro-
teome Sci. 2, 6
28. Paredes, A., Plata, C., Rivera, M., Moreno, E., Va´zquez, N., Mun˜oz-Clares,
R., Hebert, S. C., and Gamba, G. (2006) Am. J. Physiol. Renal Physiol. 290,
F1094–F1102
29. Darman, R. B., Flemmer, A., and Forbush, B. (2001) J. Biol. Chem. 276,
34359–34362
30. Flemmer, A. W., Gimenez, I., Dowd, B. F., Darman, R. B., and Forbush, B.
(2002) J. Biol. Chem. 277, 37551–37558
31. Ares, G. R., Caceres, P., Alvarez-Leefmans, F. J., and Ortiz, P. A. (2008)
Am. J. Physiol. Renal Physiol. 295, F877–F887
32. Maglova, L. M., Crowe,W. E., and Russell, J. M. (2004)Am. J. Physiol. Cell
Physiol. 286, C1324–C1334
33. Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E.,
and Welsh, M. J. (1992) Nature 358, 761–764
34. Starremans, P. G., Kersten, F. F., Knoers, N. V., van den Heuvel, L. P., and
Bindels, R. J. M. (2003) J. Am. Soc. Nephrol. 14, 1419–1426
Functional Expression of NKCC2 inMammalian Cells
DECEMBER 18, 2009•VOLUME 284•NUMBER 51 JOURNAL OF BIOLOGICAL CHEMISTRY 35357
 by guest on June 14, 2013http://www.jbc.org/Downloaded from 
35. Zaarour, N., Demaretz, S., Defontaine, N., Mordasini, D., and Laghmani,
K. (2009) J. Biol. Chem. 284, 21752–21764
36. Starremans, P. G., Kersten, F. F., van den Heuvel, L. P., Knoers, N. V., and
Bindels, R. J. (2003) J. Am. Soc. Nephrol. 14, 3039–3046
37. Moore-Hoon,M. L., and Turner, R. J. (1998)Biochim. Biophys. Acta 1373,
261–269
38. Matskevich, I., Hegney, K. L., and Flatman, P. W. (2005) BBA Biomem-
branes 1714, 25–34
39. Simard, C. F., Brunet, G. M., Daigle, N. D., Montminy, V., Caron, L., and
Isenring, P. (2004) J. Biol. Chem. 279, 40769–40777
40. Parvin, M. N., Gerelsaikhan, T., and Turner, R. J. (2007) Biochemistry 46,
9630–9637
41. Rath, A., Glibowicka,M., Nadeau, V.G., Chen,G., andDeber, C.M. (2009)
Proc. Natl. Acad. Sci. U.S.A. 106, 1760–1765
Functional Expression of NKCC2 inMammalian Cells
35358 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 51•DECEMBER 18, 2009
 by guest on June 14, 2013http://www.jbc.org/Downloaded from 
Citations
 http://www.jbc.org/content/284/51/35348#otherarticles
This article has been cited by 4 HighWire-hosted articles: 
 by guest on June 14, 2013http://www.jbc.org/Downloaded from 
